Estradiol/trimegestone transdermal patch - ProStrakan

Drug Profile

Estradiol/trimegestone transdermal patch - ProStrakan

Alternative Names: PSK 3987; Trim patch; Trimegestone/estradiol transdermal patch - ProStrakan

Latest Information Update: 17 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ProStrakan; sanofi-aventis
  • Developer ProStrakan
  • Class Estradiol congeners; Estrenes; Hormonal replacements; Norpregnadienes
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Menopausal syndrome

Most Recent Events

  • 19 Apr 2006 Clinical development is ongoing
  • 11 Oct 2005 PSK 3987 is available for licensing (
  • 22 Sep 2004 ProSkelia has merged with Strakan to form ProStrakan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top